Learn languages naturally with fresh, real content!

tap to translate recording

Explore By Region

flag Anavex's Alzheimer's drug application in Europe was withdrawn, causing its stock to drop.

flag Anavex Life Sciences shares dropped after the company withdrew its application for Alzheimer's drug Blarcamesine in the European Union following negative feedback from regulators. flag The company plans to review the agency's concerns and gather more data. flag Meanwhile, Anavex continues to discuss potential paths with the U.S. FDA.

3 Articles